OptimizeRx Corporation (OPRX)

OptimizeRx Corp. has experienced a substantial stock price increase of 227.87% between October 23, 2024, and October 22, 2025. The stock has risen by 10.95% in the previous week, 12.22% in the last month, and 280.27% over the past year. Key events include strong Q2 2025 financial results with a 55% year-over-year revenue increase, Q1 2025 financial results showing an 11% year-over-year revenue increase, a strategic partnership with Lamar Advertising, leadership advancements, insider transactions by Stephen L. Silvestro and Spangler, and participation in several investor conferences.

The demand for OptimizeRx Corp.'s products and services is influenced by seasonal trends in the pharmaceutical brand marketing industry. Pharmaceutical companies allocate the largest portion of their marketing budgets to the fourth quarter, leading to lower activity in the first quarter with gradual increases in subsequent quarters. OptimizeRx Corp. stock has shown monthly seasonality, with June historically having the highest probability of a positive return and July having the lowest.

OptimizeRx Corp. is a digital healthcare technology company providing digital health solutions to improve patient outcomes and medication adherence. Key products include the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT). The company offers Profiler for consumer insights, various banner messages, and media execution solutions across a consumer omnichannel network. It also provides pharmacy alerts and financial messaging solutions within EHR systems and ePrescribing platforms.

OptimizeRx Corp. has a significant market presence primarily across the United States, with e-prescribing coverage in all 50 states, supporting approximately 70% of U.S. healthcare providers. North America accounts for 94% of the company's total revenue, with Europe contributing 5% and other regions 1%.

OptimizeRx Corp. has a positive brand reputation due to its mission to improve patient outcomes through health information and financial assistance programs. The company has demonstrated significant revenue growth from increased adoption of its digital health solutions. Strategic partnerships with healthcare technology companies have expanded its network. OptimizeRx capitalized on the increased demand for digital health solutions during the COVID-19 pandemic. Strong financial results in Q1 and Q2 2025 reflect positively on its market standing. There have been no specific negative events impacting the brand reputation in the past year.

OptimizeRx Corp. has a mixed ownership structure, with institutional investors holding 68% of the company's shares and the top 10 shareholders holding 52%. The general public holds a 19% ownership stake. Major institutional owners include Whetstone Capital Advisors, LLC, BlackRock, Inc., Vanguard Group Inc, Royce & Associates Lp, Blair William & Co/il, Rice Hall James & Associates, Llc, Parkman Healthcare Partners LLC, First Light Asset Management, LLC, Divisadero Street Capital Management LP, Kennedy Capital Management, Inc., and Manatuck Hill Partners, LLC.